

Comparison of Immediate and Long-term Outcomes in Men and Women Undergoing Revascularisation for Chronic Limb Threatening Ischaemia in the Bypass vs. Angioplasty in Severe Ischaemia of the Leg (BASIL-1) Trial

Ruth A. Benson^{a,b,*}, Lewis A. Meecham^a, Catherine A. Hewitt^a, Andrew W. Bradbury^a

^a Department of Vascular Surgery and Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK

^b Department of Vascular Surgery, University Hospital Coventry and Warwickshire, UK

WHAT THIS PAPER ADDS

Existing data comparing men and women after revascularisation have all been extrapolated from retrospective cohort studies or national registries. The anatomical and clinical disease severity within the datasets, treatment decisions, and length of follow up are heterogeneous and therefore difficult to draw reliable conclusions from. This study is the first to compare outcomes for men and women in a randomised setting. It suggests that for infrainguinal disease, men are in fact worse off than women after limb salvage procedures in the long term.

Background: The reports from cohort studies comparing outcomes after revascularisation for chronic limb threatening ischaemia (CLTI) between men and women remain controversial. Anatomical and clinical disease severity is often heterogeneous, and treatment choice influenced by a variety of clinician and patient factors. The aim was to compare outcomes in men and women entered into the only randomised study comparing bypass and angioplasty for infra-inguinal disease causing severe limb ischaemia.

Methods: Data were obtained from BASIL-1 trial case record forms. Baseline demographics were compared, and Cox proportional hazard models were used to examine the relationship between sex and amputation free survival (AFS), overall survival (OS), and freedom from major adverse limb events (FF-MALE) using a per-protocol analysis. Data were analysed using a per-protocol analysis.

Results: A total of 452 patients were randomised into the BASIL-1 trial from 1999 to 2004. At randomisation, women were older and less likely to be smokers, to have diabetes, or to be on recommended best medical therapy. Men were more likely to present with gangrene. Ankle brachial pressure index (ABPI), post-revascularisation length of hospital stay, and 30 day morbidity and mortality were similar for men and women. At three years, female sex was associated with significantly better AFS (HR 0.65, 95% CI 0.47–0.89, $p < .01$), OS (HR 0.66 95% CI 0.46–0.95, $p = .02$) and FF-MALE (HR 0.74, 95% CI 0.57–0.96, $p = .02$).

Conclusion: In the BASIL-1 trial, women had similar short term but better long term outcomes after revascularisation. Sex is an important consideration when developing early, evidence based treatment pathway and revascularisation strategies for CLTI, and is an independent risk factor for outcomes following revascularisation as well as development of symptomatic PAD.

Keywords: Critical limb ischaemia, Chronic limb threatening ischaemia, Peripheral vascular disease, Infrainguinal bypass, Angioplasty, Sex

Article history: Received 30 October 2018, Accepted 2 March 2019, Available online 12 June 2019

Crown Copyright © 2019 Published by Elsevier B.V. on behalf of European Society for Vascular Surgery. All rights reserved.

INTRODUCTION

Owing to ageing populations, smoking, and diabetes, chronic limb threatening ischaemia (CLTI) secondary to peripheral arterial disease (PAD) is an increasing global healthcare issue.¹ CLTI is the leading cause of limb loss, and an important cause of premature mortality, worldwide.² Although excess mortality has been reported in women

suffering from other vascular conditions, such as acute myocardial infarction (MI) and ruptured abdominal aortic aneurysm,^{3–5} the influence of sex on outcomes following revascularisation specifically for CLTI remains poorly defined. Thus, studies comparing men and women often fail to clearly distinguish those with claudication or CLTI. The majority of CLTI studies exclude sex as a significant covariate, in part due to the relatively small number of women included, and the results of those that do are contradictory.^{6–11} It is generally accepted that women presenting with CLTI tend to be significantly older and less likely to be smokers than their male counterparts.¹² A disadvantage of cohort studies is their inability to assess for any possible

* Corresponding author. Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.

E-mail address: r.a.benson@bham.ac.uk (Ruth A. Benson).

1078-5884/Crown Copyright © 2019 Published by Elsevier B.V. on behalf of European Society for Vascular Surgery. All rights reserved.

<https://doi.org/10.1016/j.ejvs.2019.03.001>

impact of clinician bias and/or patient choice on decisions regarding open or endovascular revascularisation. Endovascular procedures are linked to shorter lengths of stay and fewer immediate complications; therefore they are often selected in patients with higher burdens of comorbidity. This bias has implications for outcome reporting in a non-randomised setting.

The UK NIHR HTA funded Bypass vs. Angioplasty in Severe Ischaemia of the Leg (BASIL) trial remains the only randomised controlled trial (RCT) to have compared bypass surgery (BS) first and balloon angioplasty (BA) first revascularisation strategies for CLTI.¹³ The BASIL trial dataset offers a unique opportunity to examine the impact of sex on outcomes following surgical and endovascular infra-inguinal revascularisation for CLTI, in a randomised cohort. The aim of this study was to investigate the effect of sex on immediate and long term major adverse limb events (MALE), amputation free survival (AFS), and overall survival for men and women after treatment out to three years. Secondary aims were to compare the incidence of cumulative re-intervention at one and three years following the primary intervention.

METHODS

The BASIL-1 trial

The BASIL-1 trial methods have been published previously in detail.¹⁴ Ethics approval was obtained from the Multi-Centre Research Ethics Committee for Scotland. Briefly, between August 1999 and June 2004, 452 patients presenting to 27 UK hospitals with CLTI because of infra-inguinal disease were randomised to a BS or BA first revascularisation strategy. Patients were followed up to death or study end date. All surviving patients had a minimum of three years of follow up.

Definitions of variables

An ex-smoker was defined as someone who reported that they had not smoked for at least one year. Post-revascularisation morbidity was defined as major (above ankle) amputation, myocardial infarction, cerebrovascular event, haematoma, infection (wound, chest, urinary tract), or false aneurysm within 30 days.

Endpoints

All analyses were performed based on the treatment received. AFS was defined as freedom from (above ankle) amputation or death from any cause. Re-intervention was defined as any surgical bypass, angioplasty or “other surgical” (non-bypass) intervention on the index limb following primary intervention (this did not include major amputation). Overall survival (OS) was defined as freedom from death from any cause. Major adverse limb events (MALEs) were defined as freedom from major amputation (trans-tibial or above) or any major vascular re-intervention such as thrombectomy or revision of a failed graft in the index limb during the follow up period.

Time to event was taken as the date of the first event. Cox proportional hazard models were used to examine the relationship between sex and AFS, OS, and MALE while adjusting for age, clinical presentation, ankle brachial pressure index (ABPI), and the type of revascularisation received. Time to event analyses were presented using Kaplan–Meier plots. Analysis was performed using SAS (version 9.4).

RESULTS

The analysis included a total of 433 patients who underwent BA or BS as their first procedure after randomisation. This cohort comprised 257 men (128 BS, 129 BA) and 176 women (67 BS and 109 BA). Baseline characteristics of men and women are shown in Table 1. Women were older at randomisation (74.2 vs. 71.8, $p \leq .01$) and less likely to be smokers (36% of women denied ever having smoked vs. only 9% of men, $p \leq .01$). They were also more likely to have untreated hypercholesterolaemia (15% of women vs. 9% of men) and less likely to be on an antiplatelet agent (56% vs. 61% of men), although the differences were non-significant. Rates of insulin dependent diabetes were similar, although men were more likely to suffer from non-insulin dependent diabetes. Baseline creatinine was significantly higher in men ($123 \pm 97 \mu\text{mol/L}$ vs. $102 \pm 45 \mu\text{mol/L}$, $p \leq .01$). Although baseline ABPI were similar in men and women, men were more likely to have a diagnosis of gangrene ($p \leq .05$). Baseline mobility was similar. However more men had an existing diagnosis of PAD at randomisation (19% vs. 13% of women), and 17% vs. 12% of women had already undergone a procedure in the trial leg.

At 30 days, there was no difference in post-procedural morbidity (33% vs. 29%), mortality (4% vs. 3%) or length of hospital stay. Although women showed a trend towards shorter hospital stays (median LOS 11, IQR 4–21, vs. 15, IQR 7–26) negative binomial model estimates failed to demonstrate an association. As expected, patients who underwent surgical bypass spent longer in hospital (IRR 1.71, 1.36–2.13, $p < .01$), as well as those presenting with tissue loss (2.08, 1.69–2.56, $p < .01$).

Table 2 shows the number of cumulative re-interventions at the one and three year follow up for men and women after their primary intervention. Overall, rates of re-intervention in men and women were similar. At one year, 27% of men and 26% of women had required further re-intervention, and at three years 32% had undergone re-intervention in both groups. Logistic regression models failed to find any significant factors affecting need for re-intervention including sex, primary intervention, or severity of clinical presentation.

However after three years, women were found to have significantly better AFS (HR 0.65, CI 0.47–0.89, $p < .01$) (Fig. 1), OS (HR 0.66, 0.4634–0.9487, $p = .02$) (Fig. 2) and MALE (HR 0.74, 0.57, 0.96, $p = .02$) (Fig. 3). Assessment for differences in treatment effect for sex was not statistically significant ($p = .2$ at three year follow up).

Table 1. Baseline characteristics of men and women undergoing revascularisation in the BASIL trial.

		Men (n = 269)	Women (n = 183)
Ankle pressure (mmHg)	<50	82 (30)	57 (31)
ABPI	Mean (SD, N)	0.50 (0.17, 224)	0.49 (0.16, 152)
Clinical presentation	Ischaemic rest pain only	66 (25)	50 (27)
	Tissue loss ± rest pain	203 (75)	133 (73)
Age**	Mean (SD, N)	71.8 (9.0, 269)	74.2 (8.5, 183)
	Range	39–98	40–96
Smoking status**	Never	23 (9)	66 (36)
	Current	105 (39)	59 (32)
	Ex (≥1 year)	141 (52)	58 (32)
Diabetes	Insulin dependent	46 (17)	32 (17)
	Non-insulin dependent	77 (29)	35 (19)
On an antiplatelet agent		163 (61)	103 (56)
Untreated hypercholesterolaemia		24 (9)	27 (15)
Hypertension		159 (59)	121 (66)
Angina		47 (18)	36 (20)
Stroke		34 (13)	28 (15)
COPD		28 (10)	18 (10)
CKD		9 (3)	2 (1)
IHD		94 (35)	64 (35)
Peripheral arterial disease		50 (19)	23 (13)
Previous revascularisation (same leg)		45 (17)	22 (12)
Gangrene*		91 (34)	44 (24)
Creatinine (µmol/L)**	Mean (SD, N)	123.0 (96.9, 257)	102.6 (45.0, 174)

Note. Values are given as n (%) unless stated otherwise. ABPI = arterial brachial pressure index; SD = standard deviation; N = number of patients; COPD = chronic obstruction pulmonary disease; CKD = chronic kidney disease; IHD = ischaemic heart disease; BASIL = bypass versus angioplasty in severe ischaemia of the leg.

* $p \leq .05$; ** $p \leq .01$.

DISCUSSION

The findings add to previously published studies focusing on short term outcomes, either survival to discharge or 30 day morbidity and mortality. Those studies often include a more heterogenous population, for example a mix of mild and severe limb ischaemia (SLI) or claudicants and CLTI, with differing anatomical patterns, and do not use ABPI values to classify presence of critical ischaemia. Therefore the advantage of the BASIL cohort remains its well described inclusion criteria of patients with CLTI requiring infra-inguinal treatment. Although ABPI was not part of the study inclusion criteria, values were available for inclusion in the analysis. Women were significantly older than men, with differing risk factor profiles at presentation, and an

incidence of 30 day post-revascularisation morbidity and mortality similar to men, with better AFS, OS, and MALE at long term follow up. This fits with non-randomised studies which have also noticed similar patterns of poorer outcomes for men in the longer term (out to five years) related to higher incidence of cardiovascular related death for equivalent optimisation.¹⁵ The findings suggest that the deviation in outcomes begins at between one and three years. It also suggests that post-intervention outcomes are influenced heavily by factors already present at the point of presentation. If the disparities seen between men and women are to be improved, epidemiological differences in the community need to be targeted at the earliest manifestations of symptoms.

Table 2. The number of re-interventions following primary intervention.

	Males (N = 257)	Females (N = 176)
Re-intervention at one year follow up, n (%)	70 (27)	46 (26)
Surgical bypass	34	26
Endovascular	32	24
Other surgical (non-bypass)	32	8
Re-intervention at three year follow up	81 (32)	57 (32)
Surgical bypass	42	33
Endovascular	46	34
Other surgical (non-bypass)	35	10

Note. Other surgical (non-bypass) defined as any other surgical revascularisation of the affected limb, excluding bypass or angioplasty including any relook surgery, graft thrombectomy, or angioplasty of graft anastomosis.




Figure 1. Cumulative Kaplan-Meier survival estimate of amputation free survival in men and women undergoing revascularisation in the BASIL (bypass versus angioplasty in severe ischaemia of the leg) trial. CLTI = chronic limb threatening ischaemia.

Although haemodynamic severity of disease (ABPI) was similar, men were more likely to present with gangrene or to have undergone a previous vascular intervention in the trial leg prior randomisation. This suggests men were more likely to be undergoing redo procedures. Redo surgery and the presence of tissue loss have previously been associated with worse peri-operative outcomes compared with primary procedures and patients with rest pain only.^{16,17} There are also likely to be major healthcare pathway differences between the BASIL population and cohorts described in other published non-UK national registries.

We expect there is more than one factor influencing the impact of sex on outcomes after revascularisation. The randomised nature of the group allows one aspect of bias relating to surgical approach to be removed. Several baseline characteristics that differ between the two groups have been shown, some of which are known to influence outcomes after revascularisation. This suggests that by the time patients undergo intervention for SLI, sex based differences have




Figure 2. Cumulative Kaplan-Meier survival estimate of overall survival in men and women undergoing revascularisation in the BASIL (bypass versus angioplasty in severe ischaemia of the leg) trial. CLTI = chronic limb threatening ischaemia.




Figure 3. Cumulative Kaplan-Meier survival estimate of survival without major adverse limb events (MALE) in men and women undergoing revascularisation in the BASIL (bypass versus angioplasty in severe ischaemia of the leg) trial. CLTI = chronic limb threatening ischaemia.

already manifested themselves in the pre-operative care pathway. There is awareness that women with PAD are under diagnosed or diagnosed later, with associated reductions in screening and management of associated risk factors.¹⁸

Of note, 15 of 87 women (17%) randomised to receive bypass crossed over into the angioplasty group, compared with seven out of 141 men (5%). As patients were technically suitable for both strategies it could be hypothesised that baseline features led to a change in management. However, this cannot be proven with the available data.

Although further research, including an analysis of data from ongoing UK NIHR HTA funded RCTs such as BASIL 2¹⁹ and 3²⁰ and BEST-CLI,²¹ will be required in order to more fully define the relationship between sex and outcome for CLTI, the present data from the BASIL trial supports suggestions that sex is an important factor when considering evidence based revascularisation strategies. Poorer pre-operative pathways for women, suggested here by reduced implementation and/or compliance with best medical therapy, indicate that there are further gains to be made in the optimisation of any patient in the earlier stages of peripheral vascular disease to improve immediate and longer term outcomes.

Study limitations

The trial recruited patients with rest pain or tissue loss but an ankle pressure of <math>< 50</math> mmHg was not a requirement. Therefore the population was more heterogeneous than a strict “critical limb ischaemia” cohort. However, compared with large registry data, many of which do not include ABPI to classify CLI, ABPI could be used in the modelling. Analysis of differences in sex for long term outcomes was not in the original BASIL protocol. Therefore, the findings are exploratory analyses used to generate future hypotheses relating to strategies to improve outcomes for all patients undergoing revascularisation for limb ischaemia. Finally, post-operative differences in anatomical appearances post treatment in the two groups was not analysed in the

original trial. Therefore anatomical treatment success could not be included in the analysis.

CONFLICTS OF INTEREST

None

FUNDING

The original BASIL trial was funded by the HTA. The authors received no specific funding for this work.

DISCLOSURES

The authors have nothing to disclose.

REFERENCES

- 1 Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet* 2013;**382**:1329–40.
- 2 Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, Levin-Rector A, et al. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;**380**:2071–94.
- 3 Alabas OA, Gale CP, Hall M, Rutherford MJ, Szummer K, Lawesson SS, et al. Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. *J Am Heart Assoc* 2017;**6**:e007123.
- 4 Hirsch AT, Allison MA, Gomes AS, Corriere MA, Duval S, Ershow AG, et al. A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. *Circulation* 2012;**125**:1449–72.
- 5 De Rango P, Simonte G, Manzone A, Farchioni L, Cieri E, Verzini F, et al. Mortality risk for ruptured abdominal aortic aneurysm in women. *Ann Vasc Surg* 2017;**39**:143–51.
- 6 Melvin JC, Smith JB, Kruse RL, Vogel TR. Risk factors for 30-day hospital Re-admission with an infectious complication after lower-extremity vascular procedures. *Surg Infect (larchmt)* 2017;**18**:319–26.
- 7 Ashrafi M, Salvadi R, Foden P, Thomas S, Baguneid M. Pre-operative predictors of poor outcomes in patients undergoing surgical lower extremity revascularisation – retrospective cohort study. *Int J Surg* 2017;**41**:91–6.
- 8 Brahmhatt R, Brewster LP, Shafii S, Rajani RR, Veeraswamy R, Salam A, et al. Gender and frailty predict poor outcomes in infrainguinal vascular surgery. *J Surg Res* 2016;**201**:156–65.
- 9 Lo RC, Bensley RP, Dahlberg SE, Matyal R, Hamdan AD, Wyers M, et al. Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease. *J Vasc Surg* 2014;**59**:409–18.
- 10 McCoach CE, Armstrong EJ, Singh S, Javed U, Anderson D, Yeo KK, et al. Gender-related variation in the clinical presentation and outcomes of critical limb ischemia. *Vasc Med* 2013;**18**:19–26.
- 11 Lancaster RT, Conrad MF, Patel VI, Cambria RP, LaMuraglia GM. Predictors of early graft failure after infrainguinal bypass surgery: a risk-adjusted analysis from the NSQIP. *Eur J Vasc Endovasc Surg* 2012;**43**:549–55.
- 12 Vouyouka AG, Egorova NN, Salloum A, Kleinman L, Marin M, Faries PL, et al. Lessons learned from the analysis of gender effect on risk factors and procedural outcomes of lower extremity arterial disease. *J Vasc Surg* 2010;**52**:1196–202.
- 13 Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FGR, Gillespie I, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. *J Vasc Surg* 2010;**51**:18S–31S.
- 14 Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet* 2005;**366**:1925–34.
- 15 Budtz-Lilly JW, Petersen CN, Pedersen TF, Eldrup N. Male sex associated with increased long-term cardiovascular mortality after peripheral vascular surgery for atherosclerosis despite optimal medical treatment. *Eur J Vasc Endovasc Surg* 2015;**50**:767–73.
- 16 Bodewes TCF, Ultee KHJ, Soden PA, Zettervall SL, Shean KE, Jones DW, et al. Perioperative outcomes of infrainguinal bypass surgery in patients with and without prior revascularization. *J Vasc Surg* 2017;**65**:1354–65.
- 17 Siracuse JJ, Huang ZS, Gill HL, Parrack I, Schneider DB, Connolly PH, et al. Defining risks and predicting adverse events after lower extremity bypass for critical limb ischemia. *Vasc Health Risk Manag* 2014;**10**:367–74.
- 18 Teodorescu VJ, Vavra AK, Kibbe MR. Peripheral arterial disease in women. *J Vasc Surg* 2013;**57**:18S–26S.
- 19 Popplewell MA, Davies H, Jarrett H, Bate G, Grant M, Patel S, et al. Bypass versus angioplasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. *Trials* 2016;**17**:11.
- 20 Hunt BD, Popplewell MA, Davies H, Meecham L, Jarrett H, Bate G, et al. Balloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial. *Trials* 2017;**18**:224.
- 21 Menard MT, Farber A, Assmann SF, Choudhry NK, Conte MS, Creager MA, et al. Design and rationale of the best endovascular versus best surgical therapy for patients with critical limb ischemia (BEST-CLI) trial. *J Am Heart Assoc* 2016;**5**.